Jul 9, 2026 09:37AM
Apr 30, 2026 06:22AM
Apr 30, 2026 06:00AM
Feb 5, 2026 07:24AM
Jan 8, 2026 12:08PM
Nov 20, 2025 07:45AM
Jul 3, 2025 07:41AM OS Therapies (OSTX) Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program
Jul 3, 2025 07:40AM
Jun 30, 2025 06:02AM
Jun 30, 2025 06:00AM
Jun 24, 2025 07:41AM
Jun 24, 2025 07:40AM
Jun 23, 2025 08:29PM
Jun 10, 2025 07:40AM OS Therapies (OSTX) Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
Jun 10, 2025 07:40AM
Jun 6, 2025 07:31AM
Jun 6, 2025 07:30AM
May 16, 2025 06:00AM
May 15, 2025 06:00AM
May 7, 2025 08:45AM
May 7, 2025 08:45AM OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunother
May 2, 2025 09:32AM
Apr 22, 2025 07:41AM
Apr 22, 2025 07:40AM
Apr 9, 2025 07:40AM
Apr 9, 2025 07:40AM
Apr 7, 2025 06:00AM
Apr 2, 2025 07:40AM OS Therapies to Host Analyst Day at NYSE on April 7, 2025
Mar 31, 2025 04:30PM
Mar 31, 2025 07:40AM
Mar 31, 2025 07:40AM
Mar 25, 2025 07:40AM
Mar 13, 2025 07:40AM
Mar 11, 2025 07:40AM
Feb 26, 2025 04:01PM Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
Feb 24, 2025 07:25AM
Feb 24, 2025 07:25AM
Feb 20, 2025 05:54AM
Feb 20, 2025 05:00AM
Feb 14, 2025 07:36AM
Feb 14, 2025 07:36AM
Feb 4, 2025 07:33AM OS Therapies (OSTX) Provides Corporate Update
Feb 4, 2025 07:33AM
Jan 29, 2025 09:22AM
Jan 15, 2025 07:45AM
Jan 15, 2025 07:40AM
Jan 2, 2025 11:16AM
Dec 31, 2024 03:38PM
Dec 31, 2024 03:38PM OS Therapies Announces Closing of $6 Million Private Placement
Dec 24, 2024 09:32AM

326,538 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All